7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-difluoro-4-(4-morpholinylmethyl)phenyl]-N-[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-3-pyridinyl]-, rel-

Description

BVB-808 is a selective Jak2 type 1 inhibitor. Janus kinases are critical components of signaling pathways that regulate hematopoiesis. Mutations of the non-receptor tyrosine kinase JAK2 are found in many BCR-ABL-negative myeloproliferative neoplasms. Preclinical results support that JAK2 inhibitors could show efficacy in treating chronic myeloproliferative neoplasms. JAK2 has also been postulated to play a role in BCR-ABL signal transduction. Therefore, inhibitors of JAK2 kinases are turning into therapeutic strategies for treatment of chronic myelogenous leukemia (CML).